Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORARIALS-02 open-label extension of arimoclomol in ALS
NL-OMON55065Phase 3Active, not recruiting
- Sponsor
- Orphazyme A/S
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of arimoclomol in amyotrophic lateral sclerosis (ALS), sponsored by Orphazyme A/S. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Clinical safety laboratory tests and vital signs and 2 more. Started Feb 2020; status: active, not recruiting.
02
Drugs
arimoclomol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON55065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55065.